Relief Therapeutics Holding AG (RLFTF)
USD 4.9
(0.0%)
USD 4.9
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 24.16 Million CHF | -44.3% |
| 2022 | 43.38 Million CHF | -38.1% |
| 2021 | 70.08 Million CHF | 537.05% |
| 2020 | 11 Million CHF | 97.7% |
| 2019 | 5.56 Million CHF | -61.06% |
| 2018 | 14.29 Million CHF | 42.56% |
| 2017 | 10.02 Million CHF | 9.13% |
| 2016 | 9.18 Million CHF | -26.36% |
| 2015 | 12.47 Million CHF | -18.31% |
| 2014 | 15.27 Million CHF | -39.79% |
| 2013 | 25.36 Million CHF | 538.33% |
| 2012 | 3.97 Million CHF | 41.26% |
| 2011 | 2.81 Million CHF | -52.54% |
| 2010 | 5.92 Million CHF | -30.15% |
| 2009 | 8.48 Million CHF | 9.84% |
| 2008 | 7.72 Million CHF | -47.21% |
| 2007 | 14.63 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 21.65 Million CHF | -10.38% |
| 2024 Q2 | 21.65 Million CHF | 0.0% |
| 2023 Q2 | 31.41 Million CHF | 0.0% |
| 2023 FY | 24.16 Million CHF | -44.3% |
| 2023 Q4 | 24.16 Million CHF | 0.0% |
| 2023 Q3 | 24.16 Million CHF | -23.08% |
| 2023 Q1 | 31.41 Million CHF | -27.59% |
| 2022 Q4 | 43.38 Million CHF | 0.0% |
| 2022 Q1 | 60.4 Million CHF | -13.82% |
| 2022 Q3 | 43.38 Million CHF | -28.18% |
| 2022 FY | 43.38 Million CHF | -38.1% |
| 2022 Q2 | 60.4 Million CHF | 0.0% |
| 2021 Q4 | 70.08 Million CHF | 0.0% |
| 2021 FY | 70.08 Million CHF | 537.05% |
| 2021 Q1 | 55.72 Million CHF | 406.47% |
| 2021 Q2 | 55.72 Million CHF | 0.0% |
| 2021 Q3 | 70.08 Million CHF | 25.78% |
| 2020 Q4 | 11 Million CHF | 64.38% |
| 2020 Q2 | 10.07 Million CHF | 74.77% |
| 2020 Q1 | 5.76 Million CHF | 3.63% |
| 2020 FY | 11 Million CHF | 97.7% |
| 2020 Q3 | 6.69 Million CHF | -33.59% |
| 2019 FY | 5.56 Million CHF | -61.06% |
| 2019 Q4 | 5.56 Million CHF | 97.13% |
| 2019 Q1 | 2.29 Million CHF | -83.96% |
| 2019 Q2 | 10.31 Million CHF | 349.8% |
| 2019 Q3 | 2.82 Million CHF | -72.63% |
| 2018 Q2 | 14.32 Million CHF | 625.42% |
| 2018 Q4 | 14.29 Million CHF | 629.23% |
| 2018 FY | 14.29 Million CHF | 42.56% |
| 2018 Q3 | 1.96 Million CHF | -86.32% |
| 2018 Q1 | 1.97 Million CHF | -80.3% |
| 2017 FY | 10.02 Million CHF | 9.13% |
| 2017 Q4 | 10.02 Million CHF | 392.68% |
| 2017 Q3 | 2.03 Million CHF | -78.02% |
| 2017 Q2 | 9.25 Million CHF | 438.63% |
| 2017 Q1 | 1.71 Million CHF | -81.29% |
| 2016 FY | 9.18 Million CHF | -26.36% |
| 2016 Q4 | 9.18 Million CHF | 457.8% |
| 2016 Q3 | 1.64 Million CHF | -74.11% |
| 2016 Q2 | 6.36 Million CHF | 0.0% |
| 2016 Q1 | - CHF | -100.0% |
| 2015 Q2 | 11.92 Million CHF | 0.0% |
| 2015 FY | 12.47 Million CHF | -18.31% |
| 2015 Q4 | 12.47 Million CHF | 0.0% |
| 2014 Q4 | 15.27 Million CHF | 0.0% |
| 2014 FY | 15.27 Million CHF | -39.79% |
| 2014 Q2 | 21.91 Million CHF | 0.0% |
| 2013 FY | 25.36 Million CHF | 538.33% |
| 2013 Q2 | 3.85 Million CHF | 0.0% |
| 2013 Q4 | 25.36 Million CHF | 0.0% |
| 2012 Q4 | 3.97 Million CHF | 0.0% |
| 2012 FY | 3.97 Million CHF | 41.26% |
| 2012 Q2 | 3.03 Million CHF | 0.0% |
| 2011 FY | 2.81 Million CHF | -52.54% |
| 2011 Q2 | 5.9 Million CHF | 0.0% |
| 2011 Q4 | 2.81 Million CHF | 0.0% |
| 2010 Q2 | 6.91 Million CHF | 0.0% |
| 2010 FY | 5.92 Million CHF | -30.15% |
| 2010 Q4 | 5.92 Million CHF | 0.0% |
| 2009 Q4 | 8.48 Million CHF | 0.0% |
| 2009 Q2 | 11.81 Million CHF | 0.0% |
| 2009 FY | 8.48 Million CHF | 9.84% |
| 2008 FY | 7.72 Million CHF | -47.21% |
| 2008 Q4 | 7.72 Million CHF | 0.0% |
| 2007 FY | 14.63 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 54.672% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -152.16% |
| SQZ Biotechnologies Company | 50.03 Million USD | 51.714% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 66.66% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 59.057% |
| Mesoblast Limited | 188.44 Million USD | 87.178% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -527.352% |
| Genus plc | 485 Million USD | 95.018% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -313.547% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -860.209% |
| Marizyme, Inc. | 26.67 Million USD | 9.423% |
| ContraFect Corporation | 32.53 Million USD | 25.726% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -535.842% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1119.497% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -531.249% |
| Intellipharmaceutics International Inc. | 12 Million USD | -101.203% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -105.142% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1493529.727% |
| Accustem Sciences Inc. | 1.07 Million USD | -2138.8% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 68.79% |
| EV Biologics, Inc. | 2.11 Million USD | -1042.374% |
| Q BioMed Inc. | 8.13 Million USD | -197.088% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 70.866% |
| Neon Bloom, Inc. | 1.22 Million USD | -1870.457% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -369.527% |
| Biomind Labs Inc. | 1.49 Million USD | -1512.292% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 90.101% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -31.291% |
| Skye Bioscience, Inc. | 14.07 Million USD | -71.7% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1102.012% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -16904.117% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -155.252% |
| IMV Inc. | 37.93 Million USD | 36.303% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -11913.962% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -320.514% |
| GB Sciences, Inc. | 5.41 Million USD | -345.994% |
| Alpha Cognition Inc. | 7.16 Million USD | -237.233% |
| HST Global, Inc. | 593.59 Thousand USD | -3970.466% |
| CSL Limited | 18.62 Billion USD | 99.87% |
| Halberd Corporation | 728.71 Thousand USD | -3215.681% |
| Enzolytics Inc. | 365.26 Million USD | 93.385% |
| Resverlogix Corp. | 67.39 Million USD | 64.149% |
| Affymax, Inc. | 8.87 Million USD | -172.371% |
| SYBLEU INC | 681.41 Thousand USD | -3445.867% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2780.777% |
| argenx SE | 444.95 Million USD | 94.57% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 67.75% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1309.685% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -102.989% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -559.234% |
| AVAX Technologies, Inc. | 3.99 Million USD | -504.996% |
| Zenith Capital Corp. | 27.56 Thousand USD | -87541.917% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.178% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -10024.28% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -547.028% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3448.883% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 79.648% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -167.214% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -36000.943% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1585.101% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 51.93% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -791.047% |
| BioStem Technologies, Inc. | 15.9 Million USD | -51.918% |
| ONE Bio Corp. | 27.49 Million USD | 12.125% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -5099.495% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -87976.404% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1818.848% |
| Agentix Corp. | 2.51 Million USD | -862.417% |
| LadRx Corporation | 2.2 Million USD | -998.009% |
| Cell Source, Inc. | 15.8 Million USD | -52.859% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -53958.529% |
| Regen BioPharma, Inc. | 5.45 Million USD | -342.721% |
| Regen BioPharma, Inc. | 5.45 Million USD | -342.721% |
| NovAccess Global Inc. | 7.86 Million USD | -207.376% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 2.36% |
| Itoco Inc. | 1.65 Million USD | -1361.572% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1077.735% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -299.438% |
| Kadimastem Ltd | 3.5 Million USD | -589.384% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -5631.46% |
| CytoDyn Inc. | 127.89 Million USD | 81.108% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -57705.211% |
| Mobile Lads Corp. | 1.31 Million USD | -1739.517% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1442.541% |
| Qrons Inc. | 1.48 Million USD | -1523.013% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -118.754% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2887.411% |
| Rebus Holdings, Inc. | 5.24 Million USD | -360.931% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -295.975% |
| International Stem Cell Corporation | 5.27 Million USD | -357.874% |
| Bioxytran, Inc. | 3.24 Million USD | -643.561% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -3760.922% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -423.313% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 41.063% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -8.52% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1092.957% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -341.073% |
| Neutra Corp. | 973.52 Thousand USD | -2381.898% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 16.726% |
| PureTech Health plc | 125.58 Million USD | 80.76% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -543.098% |
| IXICO plc | 1.9 Million USD | -1171.489% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -17.697% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 76.615% |
| CSL Limited | 18.62 Billion USD | 99.87% |
| Cellectis S.A. | 249.36 Million USD | 90.311% |